BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 34863244)

  • 1. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study.
    Jang JY; Kim SS; Song SY; Kim YJ; Kim SW; Choi EK
    Radiat Oncol; 2021 Dec; 16(1):231. PubMed ID: 34863244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters.
    Katsui K; Ogata T; Watanabe K; Katayama N; Kuroda M; Kiura K; Hiraki T; Maeda Y; Toyooka S; Kanazawa S
    Cancer Med; 2020 Jul; 9(13):4540-4549. PubMed ID: 32364685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis.
    Katsui K; Ogata T; Watanabe K; Katayama N; Soh J; Kuroda M; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    BMC Cancer; 2019 Nov; 19(1):1144. PubMed ID: 31771538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer.
    Sheng L; Cui X; Cheng L; Chen Y; Du X
    Radiat Oncol; 2019 Dec; 14(1):229. PubMed ID: 31842910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipsilateral lung dose as a correlative measure for radiation pneumonitis in patients treated with definitive concurrent radiochemotherapy.
    Kirakli EK; Erdem S; Susam S; Erim E
    J Cancer Res Ther; 2023; 19(5):1153-1159. PubMed ID: 37787278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
    Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
    Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
    Front Immunol; 2022; 13():918787. PubMed ID: 35795657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.
    Sugimoto T; Fujimoto D; Sato Y; Tamiya M; Yokoi T; Tamiya A; Iwasawa S; Hata A; Uchida J; Fukuda Y; Hara S; Kanazu M; Hirano K; Kokubo M; Yamamoto N
    Invest New Drugs; 2021 Jun; 39(3):853-859. PubMed ID: 33405089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters.
    Zhou Y; Yan T; Zhou X; Cao P; Luo C; Zhou L; Xu Y; Liu Y; Xue J; Wang J; Wang Y; Lu Y; Liang B; Gong Y
    Strahlenther Onkol; 2020 Jun; 196(6):505-514. PubMed ID: 31828393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-lymphocyte ratio and a dosimetric factor for predicting symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
    Lee YH; Choi HS; Jeong H; Kang KM; Song JH; Lee WS; Lee GW; Song HN; Kim HG; Kang MH; Rhee DY; Jeong BK
    Clin Respir J; 2018 Mar; 12(3):1264-1273. PubMed ID: 28618180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
    Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
    Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
    Claude L; Pérol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
    Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-Volume Parameters Predict Radiation Pneumonitis after Surgery with Induction Concurrent Chemoradiotherapy for Non-small Cell Lung Cancer.
    Ogata T; Katsui K; Yoshio K; Ihara H; Katayama N; Soh J; Kuroda M; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Acta Med Okayama; 2018 Oct; 72(5):507-513. PubMed ID: 30369608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Low dose volume histogram analysis of the lungs in prediction of acute radiation pneumonitis in patients with esophageal cancer treated with three-dimensional conformal radiotherapy].
    Shen WB; Zhu SC; Gao HM; Li YM; Liu ZK; Li J; Su JW; Wan J
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):45-9. PubMed ID: 23648300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
    Dang J; Li G; Zang S; Zhang S; Yao L
    Radiat Oncol; 2014 Jul; 9():172. PubMed ID: 25074618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors.
    Bi J; Qian J; Yang D; Sun L; Lin S; Li Y; Xue X; Nie T; Verma V; Han G
    Front Immunol; 2021; 12():828858. PubMed ID: 35095930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
    Hayashi K; Yamamoto N; Karube M; Nakajima M; Matsufuji N; Tsuji H; Ogawa K; Kamada T
    Radiat Oncol; 2017 May; 12(1):91. PubMed ID: 28558766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonitis Rates Before and After Adoption of Immunotherapy Consolidation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation.
    Yegya-Raman N; Friedes C; Lee SH; Iocolano M; Duan L; Wang X; Li B; Aggarwal C; Cohen RB; Su W; Doucette A; Levin WP; Cengel KA; DiBardino D; Teo BK; O'Reilly SE; Sun L; Bradley JD; Xiao Y; Langer CJ; Feigenberg SJ
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1445-1454. PubMed ID: 37619788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of induction chemotherapy on estimated risk of radiation pneumonitis in bulky non-small cell lung cancer.
    Amin NP; Miften M; Thornton D; Ryan N; Kavanagh B; Gaspar LE
    Med Dosim; 2013; 38(3):320-6. PubMed ID: 23611631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the predictors for radiation pneumonitis in patient with non-small cell lung cancer received radiotherapy after pneumonectomy.
    Yu JH; Wang CL; Liu Y; Wang JM; Lv CX; Liu J; Zhang Q; Fu XL; Cai XW
    Cancer Radiother; 2021 Jun; 25(4):323-329. PubMed ID: 33446419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.